A Phase 3 Multi-Center, Open Label Study Evaluating the Long Term Safety of SB204 Once Daily in the Treatment of Acne Vulgaris
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2018
At a glance
- Drugs Nitric oxide (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions; Registrational
- Sponsors Novan Inc
- 13 Feb 2018 According to a Novan media release, data will be presented at the 2018 Annual Meeting of the American Academy of Dermatology (AAD).
- 14 Dec 2017 Status changed from active, no longer recruiting to completed.
- 12 May 2017 According to a Novan media release, NDA, submission targeted in the first quarter of 2018.